Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Trex Wind-Down Inc TMBRQ

Healthcare
Trex Wind-Down, Inc., formerly Timber Pharmaceuticals, Inc., has filed a voluntary petition under Chapter 11 of the United States Bankruptcy Code and is winding down its business. The Company has no operation nor generates any revenue.

Recent & Breaking News (GREY:TMBRQ)

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

GlobeNewswire October 25, 2022

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

GlobeNewswire October 3, 2022

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

GlobeNewswire September 14, 2022

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

GlobeNewswire August 29, 2022

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

GlobeNewswire August 29, 2022

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

GlobeNewswire August 26, 2022

Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering

GlobeNewswire August 8, 2022

Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

GlobeNewswire August 4, 2022

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

GlobeNewswire June 23, 2022

Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis

GlobeNewswire May 31, 2022

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results

GlobeNewswire May 12, 2022

Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis

GlobeNewswire April 28, 2022

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results

GlobeNewswire March 31, 2022

Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting

GlobeNewswire March 25, 2022

Timber Pharmaceuticals: Invitation to the Q1 Virtual Investor Summit

Newsfile February 28, 2022

Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis

GlobeNewswire February 3, 2022

Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

GlobeNewswire January 6, 2022

Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

GlobeNewswire November 17, 2021

Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results

GlobeNewswire November 15, 2021